<DOC>
	<DOCNO>NCT02141984</DOCNO>
	<brief_summary>Approximately 600 pediatric patient prescribe Humira Injection usual practice accord approved Korean product label register observational study . Baseline data obtain enrollment include demographic , underlie disease complication especially regard purified protein derivative ( PPD ) skin test , chest X-ray . At routine visit Humira Injection administration occur accord usual medical practice , concomitant medication information adverse event information collect 70 day last administration Humira .</brief_summary>
	<brief_title>Surveillance Humira Korean JIA Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Patients diagnose polyarticular juvenile idiopathic arthritis ( JIA ) prescribe Humira physician accord local label . Polyarticular juvenile idiopathic arthritis ( JIA ) patient response previous diseasemodifying anti rheumatic drug therapy inadequate Patients give write authorization form use personal health data legal parent representative . Physician refer product market authorization ( label ) inclusion criterion . Patients know hypersensitivity Humira excipients . Patients participate clinical trial . Physician refer product market authorization ( label ) exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Korean regulatory require Postmarketing Surveillance</keyword>
</DOC>